Short Ragweed Allergy Shots: America's Best-Validated SCIT
Short ragweed allergy shots (SCIT) reduce nasal symptom scores by approximately 85% after two ragweed seasons per Creticos 2006 NEJM — a strong single-allergen efficacy signal in modern US immunotherapy. FDA-standardized Ambrosia artemisiifolia extract dosed to 6–24 µg Amb a 1 per maintenance injection is a well-established treatment. Roughly 30% of ragweed-sensitized adults also experience ragweed-melon-banana syndrome, making pre-treatment food history essential.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Short Ragweedis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Short Ragweed Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to short ragweed — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of short ragweed allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of short ragweed immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of short ragweed extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for short ragweed allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing short ragweed extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription short ragweed immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat short ragweed allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Short Ragweed?
The biology, taxonomy, and clinical fingerprint of Short Ragweed — the foundation of how SCIT targets it.
Ambrosia artemisiifolia in flower; a single plant produces up to ~1 billion pollen grains per season and pollen travels 300–400 miles by wind.
- Scientific name
- Ambrosia artemisiifolia
- Family
- AsteraceaeSunflower family
- Type
- Annual weed pollen
- Native to
- North America; now present on all continents except Antarctica
- Allergen proteins
- Amb a 1 (major) — pectate lyase, >90–95% sensitizationAmb a 4 — defensin-like (Art v 1 homolog, mugwort cross-reactivity)Amb a 6 — nsLTP (clinically relevant, melon cross-reactivity)Amb a 8 — profilin (ragweed-melon-banana syndrome mediator)Amb a 11 — cysteine protease (~65% sensitization, asthma risk)Amb a 12 — enolase (~37% sensitization, characterized 2023)
- Particle size
- 16–27 µm
- Avoidance difficulty
- Nearly impossible
How Short Ragweed Allergy Presents
Symptoms by body system — useful for distinguishing Short Ragweed sensitivity from overlapping allergies and infections.
Respiratory
- Profuse watery rhinorrhea (runny nose) peaking mid-August to mid-September
- Nasal congestion and post-nasal drip
- Sneezing in prolonged episodes during high-count mornings
- Ragweed-triggered asthma exacerbations (wheezing, chest tightness)
- Sinusitis and eustachian tube dysfunction from sustained inflammation
Ocular
- Intense itching and redness of the conjunctiva
- Bilateral tearing and photophobia during peak counts
- Eyelid swelling, especially in the morning after outdoor exposure
- Allergic shiners (under-eye darkening from venous congestion)
Skin
- Contact dermatitis after direct plant contact (weed pulling without gloves)
- Urticaria (hives) during peak season in highly sensitized individuals
- Perioral itching or mild lip tingling after eating melon, banana, or cucumber (oral allergy syndrome)
- Eczema flares coinciding with ragweed season in atopic patients
Systemic
- Fatigue and cognitive fog ('brain fog') from histamine load and disrupted sleep
- Irritability and reduced quality of life across the entire 10–12 week ragweed season
- Oral allergy syndrome: itching of lips, mouth, and throat after consuming cantaloupe, honeydew, watermelon, banana, cucumber, or zucchini
- Chamomile tea or echinacea supplement reactions (Amb a 1-family cross-reactivity) — anaphylaxis has been reported
Ragweed is one of the clearest SCIT indications we have. Creticos 2006 NEJM reset expectations for what a single-allergen shot program can achieve. I tell patients: start build-up in January or February so you reach maintenance dose before August. And I always ask about cantaloupe and chamomile before we begin — those cross-reactions matter for safety on day one.
When & Where Short Ragweed Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: mid-August through mid-September; season extends July–November in southern states· ~10–14 weeks of intense exposure in eastern US; climate change has added ~20 days to the season since 1990 (Anderegg 2021 PNAS)
US Exposure Map
23 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Moderate
- NH:
- Moderate
- WA:
- Low
- MT:
- Low
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Moderate
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- High
- MO:
- High
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Moderate
- TN:
- High
- NC:
- High
- SC:
- Moderate
- OK:
- Moderate
- LA:
- Moderate
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Moderate
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What Short Ragweed Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Short ragweed (Amb a 1) cross-reacts with other Ambrosia species through near-identical pectate-lyase epitopes, with mugwort (Artemisia) via Amb a 4 / Art v 6 homology, and with multiple foods through profilin (Amb a 8) — making ragweed one of the most network-connected pollen allergens in the US.
Amb t 5 shares >90–95% sequence identity with Amb a 1 isoallergens; short-ragweed extract delivers near-complete coverage
Amb p 5 is the A. psilostachya Group 1 ortholog; Ambrosia genus cross-reactivity is near-total
Amb a 4 and Art v 1 share ~69% sequence identity; co-sensitization is common in late-summer Asteraceae exposure
Amb a 8 (profilin) mediates itching and tingling; symptoms worsen during ragweed season
Cucurbitaceae family homology via profilin Amb a 8
Profilin cross-reactivity; also Amb a 6 nsLTP may contribute to more systemic reactions
Asteraceae family homology; anaphylaxis cases documented — warn patients before starting SCIT
Iva spp., same Heliantheae tribe; partial pollen cross-reactivity
Ragweed-Melon-Banana Syndrome
Approximately 30% of ragweed-sensitized adults experience oral allergy syndrome with cucurbit and Musaceae foods, mediated primarily by Amb a 8 (profilin) and secondarily by Amb a 6 (nsLTP). Symptoms are typically mild mouth tingling but can escalate — and chamomile tea specifically has caused anaphylaxis in Asteraceae-sensitized patients.
Is SCIT Right for Your Short Ragweed Allergy?
Answer five questions to see how strongly your symptom profile and lifestyle match the patients who benefit most from short-ragweed SCIT.
How severe are your ragweed season symptoms (August–October)?
The Short Ragweed SCIT Protocol
Short ragweed SCIT uses the only FDA-standardized weed extract in the US — Ambrosia artemisiifolia labeled in Amb a 1 µg/mL — with a target maintenance dose of 6–24 µg Amb a 1 per injection, consistent with the Creticos 2006 NEJM dosing that produced ~85% symptom reduction.
Your allergist progressively increases the Ambrosia artemisiifolia extract concentration from the most dilute starting vial toward the maintenance target dose. With Curex, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff, with a prescribed epinephrine auto-injector confirmed on hand and a brief self-observation afterward. Many allergists schedule the final build-up injections for early summer so the patient reaches maintenance before the August ragweed onset. Dose adjustments are made if you experience large local reactions.
Once the target dose (commonly 6–24 µg Amb a 1 per injection) is reached, injections shift to a maintenance schedule individualized by your allergist. Your allergist may reduce the maintenance dose during the August–October peak ragweed window to minimize systemic reaction risk, then return to the full dose after first frost. Clinical benefit — measured as significantly reduced symptom scores — typically accumulates over the first two full ragweed seasons.
Most patients who complete 3–5 years of ragweed SCIT experience lasting immune tolerance that persists for years after stopping injections. The decision to stop is individualized: patients with confirmed Amb a 1 sensitization who had severe pre-treatment symptoms often extend the course. Sustained remission has been demonstrated in SCIT for seasonal pollen allergens in long-term follow-up studies.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Short Ragweed SCIT
Short ragweed SCIT has the strongest single-allergen efficacy evidence of any US weed pollen immunotherapy, anchored by a landmark randomized double-blind placebo-controlled trial published in the New England Journal of Medicine.
- Nasal symptom score reduction85%
- Medication use reduction80%
- Symptom-medication score reduction (Phase III)65%
- Pooled symptom score improvement (meta-analysis)73%
- Ragwitek SLIT TCS reduction (comparator)27%
Short ragweed SCIT's ~85% symptom reduction per Creticos 2006 NEJM is the benchmark against which all other weed pollen immunotherapy options are measured. The Cochrane review (Calderon 2007) confirmed a number-needed-to-treat of approximately 3 for seasonal allergic rhinitis immunotherapy — meaning roughly one in three patients achieves meaningful improvement above placebo.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Short Ragweed SCIT Side Effects
Short ragweed SCIT side effects follow the standard SCIT safety profile, with local injection-site reactions being common and manageable, and serious systemic reactions being rare. With Curex's at-home program, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff, and a prescribed epinephrine auto-injector is confirmed on hand before you begin.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site redness and swelling Typically resolves within 1–4 hours; ice and antihistamines reduce discomfort | Rate 30–50% | Mild |
Localized itching at injection site | Rate 20–40% | Mild |
Large local reaction (>5 cm swelling) Prompts dose adjustment at the next visit; does not predict systemic reactions | Rate 3–10% | Moderate |
Delayed local soreness (8–24 hours post-injection) | Rate 10–20% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Nasal or ocular flare Sneezing or itchy eyes within 20 minutes; resolves with antihistamine | Rate 0.5–1% of injections | Mild |
Generalized urticaria | Rate 0.1–0.3% of injections | Moderate |
Mild asthma exacerbation Higher risk if pre-injection FEV1 <70%; spirometry screening recommended | Rate <0.1% of injections | Moderate |
Anaphylaxis A prescribed epinephrine auto-injector is always confirmed on hand; reactions typically begin within ~30 minutes, so Curex supervises the first injection from each new vial or concentration live in the Virtual Shot Room and advises a brief post-injection self-observation | Rate <0.01% of injections | Severe |
Traditionally SCIT was given only in a clinic, but for eligible patients Curex makes safe at-home self-administration possible: a personalized serum sterile-compounded to USP <797> and lot-tested, a prescribed epinephrine auto-injector confirmed on hand before the first injection, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff. The vast majority of systemic reactions occur within the first 30 minutes, so a brief post-injection self-observation is advised. Patients with uncontrolled asthma or peak-season ragweed exposure receive modified (lower) doses during August–October.
SCIT vs Alternatives for Short Ragweed
Ragweed-allergic patients have four main evidence-based options: SCIT (~85% symptom reduction at 3 years), FDA-approved Ragwitek SLIT tablet (~27% TCS reduction), avoidance measures (largely ineffective given pollen's 300-mile travel range), or daily antihistamines plus nasal corticosteroids (good short-term relief, no lasting immune modification).
| Criterion | At-Home SCIT (Curex)Best | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | ~85% symptom reduction (Creticos 2006 NEJM) | ~27% TCS reduction (Ragwitek/Nolte 2013 JACI) | Minimal — pollen travels 300–400 miles | Good short-term control; breakthrough symptoms common |
| 5-yr cost | $3,500–$12,000 over 5 yrs | $1,500–$5,000 over 3 yrs | Low (HEPA filters, masks) | $500–$3,000 over 5 yrs |
| Duration | 3–5 years | 3 years (tablets) or ongoing (drops) | Ongoing, season after season | Annual, indefinitely |
| Convenience | Self-administered weekly at home with Curex during build-up, then ongoing maintenance — no clinic visits | Daily sublingual drops or tablets at home | HEPA indoor air filtration, indoor refuge during peak | Daily or as-needed pills/sprays |
| Safety | Rare anaphylaxis (onset within ~30 min); Curex confirms a prescribed epinephrine auto-injector on hand and supervises the first injection from each new vial or concentration live in the Virtual Shot Room | Local mouth irritation; anaphylaxis very rare | No clinical risk | Antihistamine sedation, nasal steroid local effects |
| Lasting effect | Years of remission post-completion | Moderate lasting effect; less data than SCIT | No immune modification; symptoms return every fall | No lasting effect; symptoms recur if stopped |
At-Home SCIT (Curex)Best
SLIT
Avoidance
Medications
SCIT delivers the most durable outcome for short-ragweed allergy — its ~85% symptom reduction benchmark and years of post-treatment remission remain unmatched. Curex delivers that same ragweed immunotherapy as a weekly shot you give yourself at home with pricing confirmed in a current program quote — a personalized serum sterile-compounded to USP <797>, the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a prescribed epinephrine auto-injector confirmed on hand. It removes the weekly clinic trips of traditional build-up for eligible patients.
What Short Ragweed SCIT Actually Costs
Most major US health insurers cover short-ragweed SCIT under standard allergy benefits when prescribed by a board-certified allergist; actual out-of-pocket cost varies with deductible, copay, and whether your allergist bills extract preparation separately. Curex offers an at-home alternative: a personalized ragweed immunotherapy delivered as a self-administered weekly shot with pricing confirmed in a current program quote (serum, supplies, and care team, HSA/FSA eligible) — a predictable monthly option for patients with high-deductible plans or limited clinic access.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your short ragweed allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Short Ragweed SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Most patients notice measurable symptom improvement during their first full ragweed season after reaching maintenance dose — typically 3–6 months after starting the build-up phase. Creticos 2006 NEJM documented statistically significant symptom-score reductions over two consecutive ragweed seasons in patients who reached the 24 µg Amb a 1 maintenance target. Partial improvement often appears in the first season; the full ~85% reduction benchmark reflects cumulative immune re-education. This is why allergists recommend starting the build-up phase in January or February: patients who reach maintenance before the August ragweed onset get benefit in year one. If you start in September, the first full season of benefit may not come until the following fall.
Yes — antihistamines are routinely used alongside short-ragweed SCIT and do not reduce the immunologic benefit of the shots. Many allergists pre-medicate with a non-sedating antihistamine (cetirizine, loratadine, or fexofenadine) 1–2 hours before injection-day appointments to reduce local and mild systemic reactions. Oral decongestants and nasal corticosteroids are also compatible with the SCIT course. You should let your allergist know about all medications, including supplements: NSAIDs and beta-blockers require special attention because they can interfere with epinephrine response to anaphylaxis. Chamomile tea and echinacea supplements should be flagged specifically — Asteraceae family cross-reactivity has caused anaphylaxis in ragweed-sensitized patients.
Missing one injection during build-up may require repeating the previous dose rather than advancing, depending on how many weeks have elapsed. Most SCIT protocols distinguish short lapses (under 2 weeks) — where you can resume at the same dose — from medium lapses (2–8 weeks) where a step back is standard, and long lapses (over 8 weeks) where restarting from a lower vial or the beginning may be necessary. Your allergist will have a written lapse protocol for your specific extract concentration. Maintaining consistency matters most during build-up; once you're at ongoing maintenance doses, occasional delays of a week or two are generally manageable with a modest dose reduction. Always contact your allergist's office before skipping or delaying.
SCIT for short ragweed primarily targets the IgE response to Amb a 1 and other native ragweed proteins, but there is clinical evidence that reducing pollen sensitization also attenuates oral allergy syndrome (OAS) cross-reactions over time — because OAS is pollen-driven, not food-specific. The ragweed-melon-banana syndrome is mediated by Amb a 8 (profilin) and Amb a 6 (nsLTP) cross-reacting with Cucurbitaceae and Musaceae foods. Patients who complete a full ragweed SCIT course often report that raw cucumber, cantaloupe, and banana are better tolerated after 2–3 years of treatment, though individual results vary. Formally cooked versions of these foods rarely trigger OAS regardless of treatment status, because profilins are heat-labile. Your allergist should document your food reactions before you start injections.
Short ragweed SCIT is covered by most major US health insurance plans under standard allergy/immunotherapy benefits, since Ambrosia artemisiifolia extract is FDA-standardized and the indication is well-supported by clinical guidelines (AAAAI/ACAAI Practice Parameters, Cox et al. 2011 JACI). Coverage typically includes the extract preparation (CPT 95165), single injection (CPT 95115), and multi-injection visits (CPT 95117). Out-of-pocket cost depends on your plan's deductible, coinsurance rate, and whether your allergist bills the build-up and maintenance visits separately. Patients with high-deductible plans commonly pay $1,500–$4,000 before their insurance begins covering injection visits. Call your insurer ahead of time and confirm that allergy immunotherapy under your plan requires prior authorization.
Short ragweed (Ambrosia artemisiifolia) and giant ragweed (A. trifida) are both Ambrosia species sharing >90–95% Group 1 (pectate-lyase) sequence identity, which means FDA-standardized short-ragweed extract delivers near-complete cross-protection against giant ragweed IgE. The practical difference is geographic and seasonal: giant ragweed is an annual that dominates Midwest river valleys (Ohio, Indiana, Illinois), stands 12–18 feet tall, produces up to 10 million pollen grains per day, and emerges 3–4 weeks earlier (July onset) than short ragweed. A patient in Columbus, Ohio whose fall symptoms start in late July rather than mid-August is likely responding to giant ragweed. Component-resolved diagnostic testing for Amb a 1 can confirm that a standardized short-ragweed vial will provide adequate coverage without requiring a separate A. trifida extract.
Yes — SCIT for short ragweed is appropriate for children, and most guidelines support starting allergen immunotherapy as early as age 5–6 years when symptoms are severe enough to warrant it. The Ragwitek SLIT tablet (the sublingual comparator) was approved for ages 5–65 in 2021. For SCIT specifically, pediatric protocols use the same extract and dose targets as adults but may adjust the build-up schedule pace based on the child's tolerance and cooperation during the 30-minute post-injection observation window. Studies show that early initiation of SCIT in children with seasonal allergic rhinitis may reduce the risk of progressing to asthma. A large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) reported a systemic reaction rate of just 0.16% per patient across 23,614 patients and 2,021,600 injections, with no fatalities — lower than the 3%–14% typically seen with office-based shots. Note: Curex's at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection. A board-certified allergist can evaluate whether your child's symptom severity and sensitization pattern makes them a good SCIT candidate.
Ragweed pollen seasons are measurably lengthening due to anthropogenic climate change. Anderegg et al. (2021, PNAS) analyzed 60 North American pollen stations from 1990 to 2018 and found seasons starting approximately 20 days earlier and total pollen loads increasing 21%. Ragweed is particularly sensitive because it times its pollen release to photoperiod (day length) and temperature — both of which climate change is shifting. Ziska et al. (2011, PNAS) documented ragweed season extensions of up to 25 additional days in Winnipeg and 21 additional days in Fargo between 1995 and 2011. Additionally, elevated atmospheric CO₂ causes each ragweed plant to produce 2–4 times more pollen and to upregulate Amb a 1 allergen content by 1.6–1.8 times per grain. If your fall allergy has felt worse over the past decade, the data supports your experience.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.